SAKAR2026-01-012026-03-31SAKAR2026-03-31SAKAR2025-03-31SAKAR2025-04-012026-03-31SAKAR2026-01-012026-03-31in-capmkt:OtherExpenses1MemberSAKAR2025-04-012026-03-31in-capmkt:OtherExpenses1MemberSAKAR2026-03-31OtherNoncurrentFinancialAssetsDomain1SAKAR2026-03-31OtherNoncurrentFinancialAssetsDomain2SAKAR2026-03-31OtherNoncurrentFinancialAssetsDomain3SAKAR2026-03-31OtherNoncurrentAssetsDomain1SAKAR2026-03-31OtherCurrentFinancialAssetsDomain1SAKAR2026-03-31OtherCurrentAssetsDomain1SAKAR2026-03-31OtherCurrentAssetsDomain2SAKAR2026-03-31OtherCurrentAssetsDomain3SAKAR2026-03-31OtherCurrentAssetsDomain4SAKAR2026-03-31OtherCurrentAssetsDomain5SAKAR2026-03-31OtherCurrentAssetsDomain6SAKAR2026-03-31OtherNoncurrentFinancialLiabilitiesDomain1SAKAR2026-03-31OtherCurrentFinancialLiabilitiesDomain1SAKAR2026-03-31OtherCurrentFinancialLiabilitiesDomain2SAKAR2026-03-31OtherCurrentFinancialLiabilitiesDomain3SAKAR2026-03-31OtherCurrentFinancialLiabilitiesDomain4SAKAR2026-03-31OtherCurrentLiabilitiesDomain1SAKAR2026-03-31OtherCurrentLiabilitiesDomain2SAKAR2026-03-31OtherCurrentLiabilitiesDomain3SAKAR2026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1SAKAR2025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1SAKAR2026-01-012026-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares000000SAKARNOTLISTEDINE732S01012Sakar Healthcare LimitedMain BoardEquity2025-04-012026-03-312026-05-122026-05-06INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2026-05-1211:30:002026-05-1211:59:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated71097000017120007126820003577850000-7397600012938000024112000593570003542400053208200018060000001806000006229500080620007035700001102430000000110243000-2670001099760001102430000109976000222499000104.964.96004.964.960001 The figures for quarter ended on 31st March, 2026 are the balancing figures between the audited figures in respect of the full financial year ended on 31st March, 2026 and the year to date figures upto the third quarter of the financial year. <BR> <BR> 2 The Company is operating only in one segment i.e. Manufacturing Of Pharmaceutical Products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. Hence segment reporting is not given. <BR> <BR> 3 The consolidated results of the Company are comprising of wholly owned subsidiary of the Company viz. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/associate. <BR> <BR> 4 The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. <BR> <BR> 5 Figures, wherever required, are regrouped/ rearranged. There are no material adjustments made in the results of the earlier periods. <BR> <BR> 6 The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 12th May, 2026 <BR> <BR> 7 The Statutory Auditors have carried out an audit of the above results for the financial year ended 31st March, 2026 and have issued an unmodified opinion on the same. <BR> <BR> 8 Further, the figures of Standalone and Consolidated Financial Results are identical since the subsidiary company has not carried out any business transactions during the relevant reporting period. Accordingly, there is no impact on the consolidated financial statements, resulting in the same figures as the standalone financials. <BR> 2025-04-012026-03-31AuditedConsolidated251736000022874000254023400013268830000-94116000387169000785590002356450002085420002142682000397552000039755200062295000304110009270600003048460000000304846000-1068000303778000304846000030377800022249900010302202600013.713.70013.713.7000Other expenses35424000Other expenses20854200031905900003965300007427000003006000030060009799000034055090007004140005008330000421000217500000503429000200742000140458500048100940002224990003022026000324452500032445250003135300000313530000280840001285820004701960002395090000515400000515400000152300000907209000101745000086419000109537300015655690004810094000Trade and Security Deposits0Capital Advances0Right of Use Assets0Other non-current assets97990000Interest Receivable0Advances to Suppliers0Advance income tax (net of provision)0Balance with Government Authorities0Advances to Employees0Prepaid Expenses0Others200742000Lease Liability0Lease Liability0Other Payables0Payable to Selling Share holders0Other current financial liabilities152300000Statutory Payables0Advance from customers0Other current liabilities10174500073543000-264490000-1939540000-59717000047161000-9229300003047340000216140000235645000000381000002590400000000000-1129000013511800053267000000040090000049258000000000000-2835220000000000000000000000000-283522000008640000000000022241200000729670000-576000-209555000-4970000-49700030730002576000Remeasurements of the employee defined benefit plan-370000-370000Remeasurements of the employee defined benefit plan-1480000-1480000-103000-41200000-267000-1068000AuditedtrueJ S Shah & Cotrue2027-06-30